Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;18(7 Suppl 2):8-9.

Efficacy and Safety of Extended Induction Treatment With Upadacitinib 45 Mg Once Daily Followed by Maintenance Upadacitinib 15 or 30 Mg Once Daily in Patients With Moderately to Severely Active Ulcerative Colitis

No authors listed

Efficacy and Safety of Extended Induction Treatment With Upadacitinib 45 Mg Once Daily Followed by Maintenance Upadacitinib 15 or 30 Mg Once Daily in Patients With Moderately to Severely Active Ulcerative Colitis

No authors listed. Gastroenterol Hepatol (N Y). 2022 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 7.
Figure 7.
Efficacy of 16 weeks of extended induction treatment with upadacitinib in patients with moderately to severely active ulcerative colitis. Adapted from Vermeire S et al. DDW abstract 966. Gastroenterology. 2022;162(suppl 1).
See this image and copyright information in PMC

References

    1. D’Amico F, Fiorino G, Furfaro F, Allocca M, Danese S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018;27(7):595–599. - PubMed
    1. Danese S, Vermeire S, Zhou W et al. Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 U-ACHIEVE study [ECCO abstract OP24]. J Crohns Colitis. 2021;15(suppl 1)
    1. Sandborn WJ, Ghosh S, Panes J et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139–2149.e14.. - PubMed
    1. Vermeire S, Danese S, Zhou W et al. Efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study [ECCO abstract OP23]. J Crohns Colitis. 2021;15(suppl 1)
    1. Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. - PubMed

LinkOut - more resources